NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Silkland, a tech brand specializing in cables and accessories, has released the first-ever 16K VESA-certified USB C to DisplayPort 2.1 cable to support the future of visual display technology, now available on Amazon.
With support for 16K resolution, users can expect an unparalleled level of detail and realism, making the cable ideal for high-end computing, gaming, and professional applications. It is also backward compatible with 8K and 4K resolutions, ensuring a versatile and future-proof solution for all display needs.
One of the standout features of this cable is its bi-directional support, allowing it to connect USB C devices like laptops, phones, and tablets to DisplayPort monitors or connect DisplayPort devices like PC to USB C monitors. This flexibility makes it a versatile tool for a wide range of applications. Additionally, it is compatible with Thunderbolt 5/4/3, offering a plug-and-play experience with no drivers needed.
DisplayPort 2.1 integration elevates connection speeds up to 40Gbps and supports 16K@30Hz, 8K@120Hz, 4K@240Hz, crucial for reducing screen tearing in fast visuals. The stable signal transmission facilitated by gold-plated plugs paired with thicker copper wires minimizes signal loss while maximizing quality.
This innovative product also supports HDR (High Dynamic Range) and HDCP2.3 (High-bandwidth Digital Content Protection), along with G-Sync and Free Sync technologies ensuring seamless video playback without flickering issues across all formats of content display. Moreover, it facilitates Multi-Stream Transport (MST) allowing users to daisy-chain multiple monitors - enhancing productivity spaces or creating immersive gaming setups.
The cable also works seamlessly under Clamshell mode, and with DSC 1.2a, users can enjoy high-resolution and high-frame-rate video through existing physical interfaces.
Silkland has always prioritized high-end cable R&D, and this USB C to DisplayPort 2.1 cable is no exception. Certified by VESA, it guarantees top performance and reliability. The E-braided design prevents tangling, while the ergonomic aluminum shell ensures easy plugging. Gold-plated plugs and thicker copper wires enhance image transmission stability and quality.
For more information, please visit: https://www.amazon.com/dp/B0D8164MC1
About Silkland
Founded in 2019, Silkland integrates design, R&D, and sales, specializing in high-end cable development. Focusing on cutting-edge technology products, it leads the high-end cable market across the US, Europe, Japan. As a member of VESA and USB-IF, Silkland has demonstrated its commitment to quality and innovation by developing certified DP 2.1 cables, USB4 cables, and HDMI 2.1 cables.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Silkland Launches First 16K VESA-Certified USB C to DisplayPort 2.1 Cable on Amazon
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).
This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.
According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×109 PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.
By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.
"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."
About MVR-T3011
MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.
About ImmVira
ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
